Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional...
31 Julio 2020 - 3:01PM
Arcturus Therapeutics Holdings Inc. (the “Company”, Nasdaq: ARCT),
a leading clinical-stage messenger RNA medicines company focused on
the development of infectious disease vaccines and significant
opportunities within liver and respiratory rare diseases, announced
the closing on July 31, 2020 of its previously announced
underwritten public offering of 3,753,773 shares of its common
stock at a public offering price of $53.00 per share, which
included the exercise in full by the underwriters of their option
to purchase up to an additional 489,622 shares of common stock at
the public offering price, less underwriting discounts and
commissions. Arcturus received total gross proceeds from the
offering (before deducting the underwriting discounts and offering
expenses) of approximately $200 million. The Company intends to use
the net proceeds of the offering to develop, test and manufacture
the Company’s LUNAR-COV19 vaccine candidate and to continue
clinical development of LUNAR-OTC; to advance the Company’s
LUNAR-CF, LUNAR-CV and LUNAR-FLU preclinical programs into clinical
development; to fund early research and development of novel and
proprietary RNA medicines; and for general corporate and working
capital purposes.
Citigroup, Guggenheim Securities and Barclays
acted as joint book-running managers for the offering. Baird, B.
Riley FBR and H.C. Wainwright & Co. acted as co-lead managers
for the offering. Ladenburg Thalmann acted as co-manager for the
offering.
The securities described above were offered by
the Company pursuant to an effective shelf registration statement
on Form S-3 (File No. 333-238139) previously filed with the
Securities and Exchange Commission (“SEC”) on May 8, 2020 and
declared effective by the SEC on May 21, 2020.
A final prospectus supplement relating to the
offering dated July 28, 2020 was filed with the SEC on July 30,
2020 and is available on the SEC’s website at http://www.sec.gov.
Copies of the final prospectus supplement and accompanying
prospectus relating to the offering may be obtained from Citigroup
Global Markets Inc., Attention: Prospectus Department, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
New York 11717, or by telephone at (800) 831-9146; Guggenheim
Securities, LLC, Attention: Equity Syndicate Department, 330
Madison Avenue, New York, NY 10017, by telephone at (212) 518-5548,
or by email at GSEquityProspectusDelivery@guggenheimpartners.com;
or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717,
Barclaysprospectus@broadridge.com, telephone: (888) 603-5847.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy any of the
securities described herein, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Arcturus
Therapeutics Founded in 2013 and based in San Diego,
California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a
clinical-stage mRNA medicines and vaccines company with enabling
technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA
Technology and (iii) mRNA drug substance along with drug product
manufacturing expertise. Arcturus’ diverse pipeline of RNA
therapeutic candidates includes programs to potentially treat
Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis,
Glycogen Storage Disease Type 3, Hepatitis B, non-alcoholic
steatohepatitis (NASH) and a self-replicating mRNA vaccine for
SARS-CoV-2. Arcturus’ versatile RNA therapeutics platforms can be
applied toward multiple types of nucleic acid medicines including
messenger RNA, small interfering RNA, replicon RNA, antisense RNA,
microRNA, DNA, and gene editing therapeutics. Arcturus’
technologies are covered by its extensive patent portfolio (192
patents and patent applications, issued in the U.S., Europe, Japan,
China and other countries). Arcturus’ commitment to the development
of novel RNA therapeutics has led to collaborations with Janssen
Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies
of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda
Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics
Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more
information visit www.ArcturusRx.com
Forward Looking StatementsThis
press release contains forward-looking statements that involve
substantial risks and uncertainties for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995.
Any statements, other than statements of historical fact included
in this press release, including those regarding the Company’s
expected performance, development of any specific novel mRNA
therapeutics, satisfaction of the customary closing conditions to
the offering, delays in obtaining required stock exchange or other
regulatory approvals, stock price volatility, the impact of general
business and economic conditions, the expected gross proceeds from
the offering and the intended use of proceeds of the offering, are
forward-looking statements. Arcturus may not actually achieve the
plans, carry out the intentions or meet the expectations or
projections disclosed in any forward-looking statements such as the
foregoing and you should not place undue reliance on such
forward-looking statements. Such statements are based on
management’s current expectations and involve risks and
uncertainties, including those discussed under the heading "Risk
Factors" in Arcturus’ Annual Report on Form 10-K for the fiscal
year ended December 31, 2019, filed with the SEC on March 16, 2020
and in subsequent filings with, or submissions to, the SEC. Except
as otherwise required by law, Arcturus disclaims any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result
of new information, future events or circumstances or
otherwise.
IR and Media ContactsArcturus TherapeuticsNeda
Safarzadeh (858) 900-2682 IR@ArcturusRx.com
Kendall Investor RelationsCarlo Tanzi, Ph.D. (617)
914-0008 ctanzi@kendallir.com
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024